"GSK acquires efimosfermin alfa from Boston Pharma for $2bn" was originally created and published by Pharmaceutical ...

London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

GSK plc (LSE/NYSE:GSK) announced Monday the completion of its acquisition of efimosfermin alfa from Boston Pharmaceuticals. The deal includes an upfront payment of $1.2 billion and up to $800 ...

British pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...

Investigational efimosfermin alfa was safe and well tolerated among patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH), a randomized phase IIa trial showed.

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis significantly improved outcomes after 24 weeks.

CAMBRIDGE, Mass., April 23, 2025--Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing efimosfermin alfa, an investigational, once-monthly FGF21 analogue for the treatment ...

LONDON - GSK plc (LSE/NYSE:GSK) has completed its acquisition of efimosfermin alfa from Boston Pharmaceuticals, the company announced Monday. The deal, valued at up to $2 billion, includes an ...

LONDON - GSK plc (LSE/NYSE:LON: GSK) has completed its acquisition of efimosfermin alfa from Boston Pharmaceuticals, the company announced Monday. The deal, valued at up to $2 billion, includes an ...

GSK plc (LSE/NYSE:LON: GSK) announced Monday the completion of its acquisition of efimosfermin alfa from Boston Pharmaceuticals.The deal includes an upfront payment of $1.2 billion and up to $800 ...